What cost weight loss?

Circulation

Volumn 125, Issue 9, 2012, Pages 1171-1177

  Hiatt, William R ^a   Thomas, Abraham ^b   Goldfine, Allison B ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

adverse drug event; cardiovascular events; drugs; obesity; safety

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; APPETITE STIMULANT; DEXFENFLURAMINE; FENFLURAMINE; LORCASERIN; NORADRENALIN UPTAKE INHIBITOR; PHENTERMINE PLUS TOPIRAMATE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYMPTOM; COGNITIVE DEFECT; DEPRESSION; DRUG APPROVAL; DRUG SAFETY; EPIDEMIOLOGICAL DATA; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SURGICAL APPROACH; SYNCOPE; UNITED STATES; VALVULAR HEART DISEASE; WEIGHT GAIN; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; BENZAZEPINES; BUPROPION; CYCLOBUTANES; FRUCTOSE; HUMANS; NALTREXONE; OBESITY; PHENTERMINE; RISK ASSESSMENT; RISK FACTORS; WEIGHT LOSS;

EID: 84857816143     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.023499     Document Type: Review

References (17)

1. Pratt JS, Cummings S, Vineberg DA, Graeme-Cook F, Kaplan LM. Case records of the Massachusetts General Hospital: weekly clinicopathological exercises: case 25-2004: a 49-year-old woman with severe obesity, diabetes, and hypertension. N Engl J Med. 2004;351:696-705.
2. Nguyen NT, Root J, Zainabadi K, Sabio A, Chalifoux S, Stevens CM, Mavandadi S, Longoria M, Wilson SE. Accelerated growth of bariatric surgery with the introduction of minimally invasive surgery. Arch Surg. 2005;140:1198-1202. (Pubitemid 41815903)
3. Poirier P, Cornier MA, Mazzone T, Stiles S, Cummings S, Klein S, McCullough PA, Ren FC, Franklin BA. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation. 2011;123:1683-1701.
4. Sjostrom L, Gummesson A, Sjostrom CD, Narbro K, Peltonen M, Wedel H, Bengtsson C, Bouchard C, Carlsson B, Dahlgren S, Jacobson P, Karason K, Karlsson J, Larsson B, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Carlsson LM. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10:653-662.
5. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-2693. (Pubitemid 39665322)
6. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, LaMonte MJ, Stroup AM, Hunt SC. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753-761. (Pubitemid 47295642)
7. Food and Drug Administration. FDA Briefing Document: NDA 200063: Contrave (Naltrexone 4mg, 8mg/Bupropion HCL 90mg extended release tablet). Sponsor: Orexigen Therapeutics Inc. Advisory Committee: December 7, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/ Drugs/EndocrinologicandMetabolicDrugs AdvisoryCommittee/UCM235671.pdf. Accessed July 21, 2010.
8. Abbott. Advisory Committee Briefing Document for Meridia (sibutramine hydrochloride monohydrate): Endocrinologic and Metabolic Drugs Advisory Committee: Meeting on 15 September 2010. http://www. fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM225573. pdf. Accessed September 15, 2010.
9. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev. 1999;20:805-875. (Pubitemid 30647075)
10. Halford JC, Boyland EJ, Cooper SJ, Dovey TM, Huda MS, Dourish CT, Dawson GR, Wilding JP. The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. J Psychopharmacol. 2010;24:99-109.
11. Sarac F, Pehlivan M, Celebi G, Saygili F, Yilmaz C, Kabalak T. Effects of sibutramine on thermogenesis in obese patients assessed via immersion calorimetry. Adv Ther. 2006;23:1016-1029. (Pubitemid 46341059)
12. Food and Drug Administration, Center for Drug Evaluation and Research. Endocrinologic and Metabolic Drugs Advisory Committee meeting [transcript]. September 15, 2010. http://www.fda.gov/downloads/Advisory Committees/ CommitteesMeetingMaterials/Drugs/Endocrinologicand MetabolicDrugsAdvisoryCommittee/UCM232442.pdf. Accessed September 15, 2010.
13. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905-917.
14. Cowley MA, Pronchuk N, Fan W, Dinulescu DM, Colmers WF, Cone RD. Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Neuron. 1999;24:155-163. (Pubitemid 29466155)
15. Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, Horvath TL, Cone RD, Low MJ. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature. 2001;411: 480-484. (Pubitemid 32494394)
16. Patel MR, Donahue M, Wilson PW, Califf RM. Clinical trial issues in weight-loss therapy. Am Heart J. 2006;151:633-642. (Pubitemid 43290254)
17. Brass EP, Lewis RJ, Lipicky R, Murphy J, Hiatt WR. Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk. Clin Pharmacol Ther. 2006;79:165-172.